The largest database of trusted experimental protocols

6 protocols using anti pd 1 29f 1a12

1

Immune Cell Profiling in Draining Lymph Nodes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Draining lymph nodes (dLNs) were harvested and single-cell suspensions were prepared. For the exclusion of dead cells, the Zombie fixable viability kit (BioLegend) was used. Cells were incubated in FACS staining buffer (PBS containing 1% BSA and 5 mM EDTA) with anti-FcγIII/II receptor antibody (BD), and anti-CD45 (30-F11, BioLegend), anti-CD4 (Gk1.5, BioLegend), anti-CD8 (53–6.7, BioLegend), anti-CD3e (145-2C11, BioLegend), anti-B220 (RA3-6B2, eBioscience), and anti-PD-1 (29F.1A12, BioLegend) antibodies. For intracellular IFN-γ and Gzm B staining, cells were stimulated with 25 ng/ml PMA and 1 µg/ml Ionomycin in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM l-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin (complete RPMI) with monensin (Golgi Stop, BD). After five hours of incubation, cell surface staining was followed by intracellular cytokine staining using the Fix/Perm Kit (BD) in accordance with the manufacturer’s instructions with anti–IFN-γ (XMG1.2, BD) and anti-Gzm B (NGZB, eBioscience) antibodies. Fluorescence-minus-one controls were used as negative controls. Cells were acquired on the Gallios (Beckman-Coulter) and data were analyzed using the FlowJo software (v7.6.5).
+ Open protocol
+ Expand
2

Multiparameter Analysis of Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tissues were excised from mice, minced and digested in Collagenase for 30 min. The samples were filtered through a 40-μm filter. Erythrocytes were removed with Lysing buffer (BD Biosciences). The samples were then incubated for 10 min with anti-CD16/CD32 blocking antibodies (BD Biosciences). The cells were stained with the following antibodies: anti-CD206 (C068C2, BioLegend), anti-CD11c (HL3, BD Biosciences), anti-CD11b (M1/70, BioLegend), anti-CD45 (30-F11, eBioscience), anti-F4/80 (CI: A3-1, BD Bioscience), anti-I-A/I-E (M5/114.15.2, BioLegend), anti-CD8a (53-6.7, BioLegend), anti-CD4 (GK1.5, BioLegend), anti-TCRβ (H57-597, BioLegend), anti-PD-1 (29F.1A12, BioLegend), and anti-CD44 (IM7, BioLegend). The samples were washed, incubated with 7-amino-actinomycin D (BD Biosciences) and then analysed on a FACSAria II (BD Biosciences).
+ Open protocol
+ Expand
3

Enhancing CAR-T Cell Proliferation

Check if the same lab product or an alternative is used in the 5 most similar protocols
CAR-T were labeled with 1 µM carboxyfluorescein diacetate succinimidyl ester (CFSE, Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol and were added at a 5:1 ratio with L-MDSC from tumor-bearing livers. CEA+ tumor cells were irradiated with 5000 rad and added to the culture at a 1:2 ratio with CAR-T to stimulate proliferation. The effect of in vitro blockade of PD-1 and PD-L1 signaling was examined by adding 5µg/mL anti-PD-1 (29F.1A12, Biolegend), 5µg/mL anti-PD-L1 (MIH5, eBioscience), or 10µg/mL sodium stibogluconate (SSG, EMD Millipore, Billerica, MA) to the culture. After 2–4 days CAR-T were analyzed for CFSE dilution. Proliferation represents the percentage of cells with diluted CFSE, in reference to the undivided CFSE peak and an unstimulated cell sample (negative control).
+ Open protocol
+ Expand
4

Multiparameter Flow Cytometry Antibodies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies for flow cytometry were from eBioscience (UK) except where otherwise indicated: anti-Vα2 (B20.1), anti-DO11.10 TCR (KJ1-26), anti-CD28 (37.51), anti-IL-2 (JES6-5h4), anti-CD4 (GK1.5), anti-B220 (RA3-6B2), anti-ICOS (C378.4A; BioLegend, UK), anti-CD44 (IM7; BioLegend), anti-Ki67 (SolA15), anti-Bcl-6 (K112-91; Becton Dickinson, UK), anti-CXCR5 (2G8; Becton Dickinson), anti-IFNγ (XMG1.2), anti-CD45.1 (A20; BioLegend), anti-CD45.1 (104), anti-CXCR3 (CXCR3-173; BioLegend), anti-CD62L (MEL-14), anti-Bcl-XL (7B2.5; AbCam), anti-PD-1 (29F.1A12; BioLegend), anti-CD8 (53-6.7), anti-IL-17A (eBio17B7), anti-Rorγt (B2D), anti-Tbet (eBio4B10), and anti-CD45 (30-F11). Active Caspases were detected by binding of the inhibitor VAD-FMK conjugated to sulfo-rhodamine (AbCam).
+ Open protocol
+ Expand
5

Multiparameter Flow Cytometry for Immune Cell Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Different combinations of the following fluorescence-labeled antibodies were used for flow cytometry: For analysis of DC subsets in the lymph nodes a combination of CD103 (2E7, BioLegend), CD11c (N418, BioLegend) anti-CD16/32 (93, BioLegend) and MHC-II (M5/114.15.2, BioLegend) was used. For analysis of Tfh cells and GC B cells in spleen and lymph nodes a combination of anti-CD4 (RM4-5, BioLegend), anti-CD19 (1D3, BioLegend), anti-B220 (RA3-6B2, eBioscience), anti-CD16/32 (93, BioLegend), anti-PD1 (29F.1A12, BioLegend), anti-CXCR5 (L138D7, BioLegend), anti-CD44 (IM7, BioLegend), anti-FAS (SA367H8, BioLegend), anti-IgG1 (A85-1, BD Biosciences) and anti-GL7 (GL7, BioLegend) was used.
+ Open protocol
+ Expand
6

Multiparametric Flow Cytometry Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Single cell suspensions obtained from the intestinal mucosa or MLNs were stained and analyzed on FACSCanto II (Becton Dickinson, Franklin Lakes, NJ, USA) using FlowJo software v10.8.2 (TreeStar, Ashland, OR, USA). The following antibodies were used: anti-B220 (RA3-6B2; BioLegend), anti-CD38 (90; BioLegend), anti-CD45 (30-F11; BioLegend), anti-GL7 (GL7; BioLegend), anti-CD138 (281-2; BioLegend), anti-CD4 (GK1.5; BioLegend), anti-CXCR5 (L138D7, BioLegend), anti-PD-1 (29F.1A12, BioLegend), anti-Siglec-F (E50-2440, BD Biosciences, Franklin Lakes, NJ, USA), anti-CD11c (N418, BioLegend), anti-I-A/I-E (M5/114.15.2, BioLegend), anti-IgE (RME-1, BioLegend), anti-CD103 (W19396D, BioLegend), anti-CD11b (M1/70, BioLegend), anti-IL-7Rα (A7R34, BioLegend), anti-CCR6 (29-2L17, BioLegend), anti-TCRβ (H57-597, BioLegend), and anti-TCRγδ (UC7-13D5, BioLegend). Dead cells were gated out using a Zombie NIR Fixable Viability Kit (BioLegend). Before staining, Fc receptors were blocked with an anti-CD16/32 antibody (2.4G2, BioLegend). Negative controls consisted of isotype-matched, directly conjugated, nonspecific antibodies (BD Biosciences). Intracellular staining was performed using anti-Foxp3 antibody (FJK-16s; Thermo Fisher Scientific) and anti-RORγt antibody (Q31-378; BD Biosciences), as described previously [29 (link)].
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!